## SUPPLEMENTAL TABLE

Table S1. Least squares mean change from baseline in primary and secondary efficacy outcome measures on day 8 and study end (visit 4, day 15), carbetocin versus placebo

Outcome measure	Day 8		Day 15	
	LS Mean Change	*P* Value	**LS Mean Change**	*P* Value
HPWSQ-R total score	–5.2	0.0632	–6.7	0.0290
Behavior	–1.9	0.1153	–2.0	0.1172
Drive	–2.1	0.0625	–1.6	0.1436
Severity	–1.1	0.0572	–1.5	0.0248
HPWSQ-R-C total score	–10.2	0.0017	–10.5	0.0014
Behavior	–5.4	0.0017	–4.3	0.0068
Drive	–3.4	0.0019	–2.6	0.0340
Severity	–1.7	0.0061	–2.2	0.0014
CGI-I	–0.9	0.0162	–0.8	0.0233
CY-BOCS	–2.7	0.0956	–6.2	0.0047
Food domain score of Reiss Profile	–3.0	0.0184	–4.4	0.0132

CGI-I, Clinical Global Impressions–Improvement; CY- BOCS, Children's Yale-Brown Obsessive Compulsive Scale; HPWSQ-R, parent/caregiver-rated Hyperphagia in Prader-Willi Syndrome Questionnaire-Responsiveness; HPWSQ-R-C, clinician-rated Hyperphagia in Prader-Willi Syndrome Questionnaire-Responsiveness; LS, least squares.

SUPPLEMENTAL FIGURES

Figure S1. Change from baseline in HPWSQ-C total score at day 8 and study end (visit 4, day 15). The analysis included all participants with an HPWSQ-C assessment at baseline, day 8, and/or day 15 and was performed using an ANCOVA model with treatment group and study site as fixed effects.


ANCOVA, analysis of covariance; HPWSQ-C, clinician-rated Hyperphagia in Prader-Willi Syndrome Questionnaire-Responsiveness; LS, least squares; SE, standard error.

Figure S2. Change from baseline in CY-BOCS total score at day 8 and study end (visit 4, day 15). The analysis included all participants with a CY-BOCS assessment at baseline, day 8, and/or day 15 and was performed using an ANCOVA model with treatment group and study site as fixed effects.


ANCOVA, analysis of covariance; CY-BOCS, Children's Yale-Brown Obsessive Compulsive Scale; LS, least squares; SE, standard error.

Figure S3. Change from baseline in CGI-I total score at day 8 and study end (visit 4, day 15). The analysis included all participants with a CGI-I assessment at baseline, day 8, and/or day 15 and was performed using an ANCOVA model with treatment group and study site as fixed effects.

ANCOVA, analysis of covariance; CGI-I, Clinical Global Impression–Improvement; LS, least squares; SE, standard error.

Figure S4. Change from baseline in Food domain score of Reiss Profile total score at day 8 and study end (visit 4, day 15). The analysis included all participants with a food domain score of the Reiss Profile assessment at baseline, day 8, and/or day 15 and was performed using an ANCOVA model with treatment group and study site as fixed effects.

ANCOVA, analysis of covariance; LS, least squares; SE, standard error.